Randomized Controlled Trials of the D1/D5 Antagonist Ecopipam for Weight Loss in Obese Subjects
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Objective: To evaluate the efficacy and safety of the selective dopamine D1/D5 antagonist ecopipam for the treatment of obesity. Research Methods and Procedures: Four randomized, double‐blind, multicenter trials compared ecopipam (n = 1667) and placebo (n = 1118) in obese subjects including type 2 diabetic subjects. Subjects received oral ecopipam 10, 30, or 100 mg daily for 12 weeks (Phase 2) or 50 or 100 mg daily for 52 weeks (Phase 3) combined with a weight loss program. Primary efficacy variables were the proportion of subjects with ≥5% weight loss from baseline at 12 weeks (Phase 2) or the distribution of percentage weight loss from baseline at 52 weeks (Phase 3). Results: In the Phase 2 study, 26% of subjects administered ecopipam 100 mg vs. 6% of placebo subjects achieved ≥5% weight loss after 12 weeks (p < 0.01). In the Phase 3 studies, ecopipam 100 mg produced a 3.1% to 4.3% greater weight loss than placebo at 52 weeks. More subjects administered ecopipam vs. placebo achieved a 5% to 10% or >10% weight loss in two non‐diabetic phase 3 trials. Ecopipam‐treated subjects also maintained more weight loss compared with placebo subjects at 52 weeks. Phase 3 studies were discontinued because of unexpected psychiatric adverse events (ecopipam 31% vs. placebo 15%), including depression, anxiety, and suicidal ideation. Discussion: Ecopipam was effective for achieving and maintaining weight loss in obese subjects, including type 2 diabetic subjects; however, the adverse effects on mood observed in the Phase 3 studies exclude its projected use in weight management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
The Continuing Epidemics of Obesity and Diabetes in the United States
Mokdad, A. H. (2001) · JAMA · doi:10.1001/jama.286.10.1195 · Cited by 2,730
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915 · cited 3×
“loss of 3% achieved with orlistat was recently shown to be sufficient to reduce the incidence of type 2 diabetes in non-diabetic obese patients (28).”
BackgroundObesity and the risk of new-onset atrial fibrillation
Wang, T. J. (2004) · JAMA · doi:10.1001/jama.292.20.2471 · Cited by 1,427 · cited 8×
“Pharyngitis 48 (11) 56 (13) 51 (12) 33 (8) 23 (5) 7 (4) 7 (4) 88 (8) 137 (9)”
BackgroundInfluentialEffects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392
Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events
Horvitz, J. C. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00019-1 · Cited by 967
Onyike, C. U. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg275 · Cited by 827 · cited 2×
“Obesity has been shown to be associated with depression in the general population and in clinical samples (31), especially in women and in severely obese men (32).”
BackgroundLong-term pharmacotherapy for obesity and overweight
Padwal, R. S., Rucker, D., Li, S. K., Curioni, C., & Lau, D. C. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004094.pub2 · Cited by 384
Cannabinoids Enhance Subsecond Dopamine Release in the Nucleus Accumbens of Awake Rats
Cheer, J. F., Wassum, K. M., Heien, M. L. A. V., Phillips, P. E. M., & Wightman, R. M. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-04.2004 · Cited by 343
HOEBEL, B. G., HERNANDEZ, L., SCHWARTZ, D. H., MARK, G. P., & HUNTER, G. A. (1989) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1989.tb53242.x · Cited by 220 · cited 5×
“A role for D1-like receptors in food intake has been established in animal models (16,17).”
BackgroundInfluentialBupropion SR vs. Placebo for Weight Loss in Obese Patients with Depressive Symptoms
Jain, A. K., Kaplan, R. A., Gadde, K. M., Wadden, T. A., Allison, D. B., Brewer, E. R., Leadbetter, R. A., Richard, N., Haight, B., Jamerson, B. D., et al. (2002) · Obesity Research · doi:10.1038/oby.2002.142 · Cited by 205
Reduced cerebrospinal HVA concentrations and HVA/5-HIAA ratios in suicide attempters
Engström, G., Alling, C., Blennow, K., Regnéll, G., & Träskman-Bendz, L. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00016-4 · Cited by 157
Brain monoamine receptors in a chronic unpredictable stress model in rats
Ossowska, G., Nowak, G., Kata, R., Klenk-Majewska, B., Danilczuk, Z., & Żebrowska-Łupina, I. (2001) · Journal of Neural Transmission · doi:10.1007/s007020170077 · Cited by 76 · cited 1×
“In addition, an increase in limbic D1 receptor expression has been reported in a validated animal model of depression (41).”
Background
Cited by
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097
Self-citationZhang, A., Neumeyer, J. L., & Baldessarini, R. J. (2007) · Chemical Reviews · doi:10.1021/cr050263h · Cited by 428
An integrative perspective on the role of dopamine in schizophrenia
Maia, T. V., & Frank, M. J. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.021 · Cited by 293
“, with dopamine agonists in Parkinson’s disease) impairs NoGo learning (110,111), which in schizophrenia is preserved.”
Centrally Acting Agents for Obesity: Past, Present, and Future
Coulter, A. A., Rebello, C. J., & Greenway, F. L. (2018) · Drugs · doi:10.1007/s40265-018-0946-y · Cited by 151
Self-citationMedical treatment of obesity: The past, the present and the future
Bray, G. A. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.015 · Cited by 109
“Ecopipamwas in development as an obesity drug but its development was recently terminated [24].”
Background
Metadata
- Authors
- Astrup, A., Greenway, F. L., Ling, W., Pedicone, L., Lachowicz, J., Strader, C. D., Kwan, R., & Ecopipam Obesity Study Group
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2007-07
- Volume
- 15
- Issue
- 7
- Pages
- 1717-1731
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W2023901054
- Cited by
- 64
- References
- 14
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.